Exercise on TB clinical epidemiology: what are the indicators suggesting? G.B. Migliori WHO Collaborating Centre for Control of TB and Lung Diseases,

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
International Standards of Tuberculosis Care Implementation by Pulmonologists in Private Practice in Jakarta E. Burhan 1, M. A. Nawas 1, D. Kusumo Sutoyo.
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Implementation of Management information system in Ukraine. PATH Project team “TB Control partnership in Ukraine”
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Revised National Tuberculosis Control Programme (RNTCP)
Diagnosis of TB.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
1 TB/HIV Project in the Philippines Yumiko Yanase.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
DEPARTMENT OF HEALTH DOTS Program for TB (Tuberculosis Directly Observed Short-course)
Monitoring and Evaluation Module 12 – March 2010.
Progress of the Singapore TB Elimination Programme (STEP)
Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
Surveillance Data in Action: Tuberculosis Indicators Melissa Ehman, MPH Tuberculosis Control Branch (TBCB) Division of Communicable Disease Control Center.
Course presentation GB Migliori WHO Collaborating Centre for TB and Lung Diseases; Fondazione S. Maugeri, Tradate Italy C. Lange Research Center Borstel,
NATIONAL TB 2012 INDICATOR ANALYSIS REPORT Presented by: Sandile Ginindza Lugogo Sun Hotel 05 th -7 th June 2013 Ministry of Health NTCP.
PMDT expansion is first of all expansion of DR-TB detection services Workshop on the development and implementation of supervision and patient support.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
Tuberculosis control in Suriname Situational analysis.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.
Contribution of operational research in China National Center for TB Control and Prevention, China CDC Jiang Shiwen Cancun.
1 Identifying Contribution of Community-based DOTS in Treatment Outcome of TB Patients in Four Provinces of Afghanistan Qader, Ghulam MD, DPH, MPH Senior.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Rauni Ruohonen FILHA Priorities of TB control in penitentiary care.
ZAMSTAR restricted randomisation CREATE Investigators Meeting 2005 Charalambos (Babis) Sismanidis LSHTM.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Monitoring and Evaluation Frameworks
TB- HIV Collaborative activities in Romania- may 2006 status
Philippe Glaziou Geneva, 12 October 2009
Cascade of care for persons newly diagnosed
PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED
PROGRESS IN GLOBAL TB CONTROL
اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
بسم الله الرحمن الرحيم.
World Tuberculosis Day 2016
Implementing a TB-Control Program in Prisons: The Basics
Community Pharmacists Monitoring of Pulmonary Tuberculosis Outpatients (Preliminary Study)
SURVEILLANCE AND EPIDEMIOLOGY OF TUBERCULOSIS IN FIJI
TB epidemiological situation in Kyrgyzstan
Success and failure in TB surveillance in Hungary
DOTS IMPACT TO TUBERCULOSIS IN LITHUANIA
National Tuberculosis Control Program Department of Health Philippines Dr. Vivian S. Lofranco Medical Specialist IV.
Cheng shiming National TB Center in China May,3, 2004
SLOVENIA.
TB epidemiology in Bulgaria
Epidemiology of Tuberculosis in Hong Kong
PROGRESS IN GLOBAL TB CONTROL
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
TB SUREVEILLANCE MEETING: OBJECTIVES
TB notification in Hong Kong
Issues on the current information system
Monitoring and Evaluation: A Review of Terms
Presentation transcript:

Exercise on TB clinical epidemiology: what are the indicators suggesting? G.B. Migliori WHO Collaborating Centre for Control of TB and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy G. Sotgiu Hygiene and Preventive Medicine Institute University of Sassari Medical School, Italy

Learning Objectives To discuss the meaning of the main outcome indicators To interpret what indicators are suggesting To use evidence from data to take decisions

TB TRANSMISSION MODEL 1 SOURCE 20 INFECTED 10 INFECTIONS X 2 YRS = 20 10% LIFETIME BREAKDOWN 50% SMEAR POSITIVE IN ABSENCE OF INTERVENTIONS

TB TRANSMISSION MODEL 5 INFECTED 10 INFECTIONS X 0.5 YR = 5 10% LIFETIME BREAKDOWN 50% SMEAR POSITIVE WITH EARLY DIAGNOSIS & TREATMENT 1 SOURCE 0.25 SOURCE

TB TRANSMISSION MODEL 30 INFECTED 10 INFECTIONS X 3 YRS = 30 10% LIFETIME BREAKDOWN 50% SMEAR POSITIVE WITH IRREGULAR TREATMENT 1 SOURCE 1.5 SOURCES

NTP Targets To cure 85% of sputum smear positive tuberculosis cases detected and To detect 70% of the estimated new sputum smear positive tuberculosis cases

70/85: the best compromise to achieve 40% reduction in transmission success rate > CDR, < success rate 40% reduction in transmission

Results expected in a good programme Success rate > 85% If mathematics are not an opinion, we have max 15% for negative outcomes: Death rate < 5% Other unsatisfactory outcomes (Default, Failure) < 10%

What are the targets suggesting? Case finding: < 70% = 70% > 70%

What are the targets suggesting? Treatment outcomes: Success > 85% Success 75-85% Success < 75% Different combinations of cure and treatment completion

What are the targets suggesting? Other outcomes: high/ low default rate high/ low death rate high/ low failure rate high/ low transfer-out rate

Fictitia

Yahoo Oblast DOTS newly implemented Case detection: 50% 30% are SS+, 15% culture + cases Success 80% (60% cure; 20% completion) Failure 5%; Death 7%; Default 8% What do you need to ask/ investigate/ check?

Wanadoo Oblast DOTS implemented since 3 years Case detection: 70% 70% bacteriologically confirmed Success 88% (85% cure; 0% completion) Failure 0%; Death 8%; Default 4% What do you need to ask/ investigate/ check ?

Tiscali Oblast DOTS implemented since 1998 Case detection: 60% 95% are SS+ Success 80% (75% cure; 5% completion) Failure 5%; Death 4%; Default 11% What do you need to ask/ investigate/ check ?

Hotmail Oblast DOTS implemented since 1998 Case detection: 60% 95% are SS+ Success 75% (55% cure; 20% completion) Failure 5%; Death 12%; Default 8% What do you need to ask/ investigate/ check ?

Asianet Oblast DOTS implemented since 5 yrs Case detection: 50% 20% are SS+ and/or culture + cases Success 60% (30% cure; 30% completion) Failure 8%; Death 12%; Default 15% Transferred out 5% What do you need to ask/ investigate/ check ?